|
1
|
Early Breast Cancer Trialists
Collaborative Group (EBCTCG), . Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year
survival: An overview of the randomised trials. Lancet.
365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Normanno N, Di Maio M, De Maio E, De Luca
A, de Matteis A, Giordano A and Perrone F: NCI-Naple Breast Cancer
Group: Mechanisms of endocrine resistance and novel therapeutic
strategies in breast cancer. Endocr Relat Cancer. 12:721–747. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baek D, Villén J, Shin C, Camargo FD, Gygi
SP and Bartel DP: The impact of microRNAs on protein output.
Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ward A, Balwierz A, Zhang JD, Küblbeck M,
Pawitan Y, Hielscher T, Wiemann S and Sahin Ö: Re-expression of
microRNA-375 reverses both tamoxifen resistance and accompanying
EMT-like properties in breast cancer. Oncogene. 32:1173–1182. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu Y, Chopp M, Zheng X, Katakowski M,
Buller B and Jiang F: MiR-145 reduces ADAM17 expression and
inhibits in vitro migration and invasion of glioma cells. Oncol
Rep. 29:67–72. 2013.PubMed/NCBI
|
|
9
|
Tang L, Chen F, Pang EJ, Zhang ZQ, Jin BW
and Dong WF: MicroRNA-182 inhibits proliferation through targeting
oncogenic ANUBL1 in gastric cancer. Oncol Rep. 33:1707–1716.
2015.PubMed/NCBI
|
|
10
|
Kurrey NK, Jalgaonkar SP, Joglekar AV,
Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA: Snail and slug
mediate radioresistance and chemoresistance by antagonizing
p53-mediated apoptosis and acquiring a stem-like phenotype in
ovarian cancer cells. Stem Cells. 27:2059–2068. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morel AP, Lièvre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Santisteban M, Reiman JM, Asiedu MK,
Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC,
Manjili MH, et al: Immune-induced epithelial to mesenchymal
transition in vivo generates breast cancer stem cells. Cancer Res.
69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park SY, Lee HE, Li H, Shipitsin M, Gelman
R and Polyak K: Heterogeneity for stem cell-related markers
according to tumor subtype and histologic stage in breast cancer.
Clin Cancer Res. 16:876e87. 2010. View Article : Google Scholar
|
|
15
|
Mansour SF and Atwa MM:
Clinicopathological significance of CD133 and ALDH1 cancer stem
cell marker expression in invasive ductal breast carcinoma. Asian
Pac J Cancer Prev. 16:7491–7496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pasquinelli AE, Reinhart BJ, Slack F,
Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B,
Müller P, et al: Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature.
408:86–89. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reinhart BJ, Slack FJ, Basson M,
Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eklund E: The role of Hox proteins in
leukemogenesis: Insights into key regulatory events in
hematopoiesis. Crit Rev Oncog. 16:65–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palakurthy RK, Wajapeyee N, Santra MK,
Gazin C, Lin L, Gobeil S and Green MR: Epigenetic silencing of the
RASSF1A tumor suppressor gene through HOXB3-mediated induction of
DNMT3B expression. Mol Cell. 36:219–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang Y, Hu J, Li J, Liu Y, Yu J, Zhuang
X, Mu L, Kong X, Hong D, Yang Q, et al: Epigenetic activation of
TWIST1 by MTDH promotes cancer stem-like cell traits in breast
cancer. Cancer Res. 75:3672–3680. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dirks P: Cancer stem cells: Invitation to
a second round. Nature. 466:40–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: Mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Frank NY, Schatton T and Frank MH: The
therapeutic promise of the cancer stem cell concept. J Clin Invest.
120:41–50. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang C, Ang BT and Pervaiz S: Cancer stem
cell: Target for anti-cancer therapy. FASEB J. 21:3777–3785. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takaishi S, Okumura T, Tu S, Wang SS,
Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rutella S, Bonanno G, Procoli A, Mariotti
A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A,
et al: Cells with characteristics of cancer stem/progenitor cells
express the CD133 antigen in human endometrial tumors. Clin Cancer
Res. 15:4299–4311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu H, Zhang HW, Sun XF, Guo XH, He YN,
Cui SD and Fan QX: Tamoxifen-resistant breast cancer cells possess
cancer stem-like cell properties. Chin Med J (Engl). 126:3030–3034.
2013.PubMed/NCBI
|
|
30
|
Wu X, Chen H, Parker B, Rubin E, Zhu T,
Lee JS, Argani P and Sukumar S: HOXB7, a homeodomain protein, is
overexpressed in breast cancer and confers epithelial-mesenchymal
transition. Cancer Res. 66:9527–9534. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shah N, Jin K, Cruz LA, Park S, Sadik H,
Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, et al: HOXB13
mediates tamoxifen resistance and invasiveness in human breast
cancer by suppressing ERα and inducing IL-6 expression. Cancer Res.
73:5449–5458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim MR, Choi HK, Cho KB, Kim HS and Kang
KW: Involvement of Pin1 induction in epithelial-mesenchymal
transition of tamoxifen-resistant breast cancer cells. Cancer Sci.
100:1834–1841. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wan L, Lu X, Yuan S, Wei Y, Guo F, Shen M,
Yuan M, Chakrabarti R, Hua Y, Smith HA, et al: MTDH-SND1
interaction is crucial for expansion and activity of
tumor-initiating cells in diverse oncogene- and carcinogen-induced
mammary tumors. Cancer Cell. 26:92–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
